Want to see HK:8049 full AI Analyst Report?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (8049) Price & Analysis

1 Followers

8049 Stock Chart & Stats

HK$2.16

-HK$0.03(-2.08%)

At close: Jan 09 4:00 PM EST

HK$2.16

-HK$0.03(-2.08%)

Day’s Range― - ―

52-Week RangeHK$1.82 - HK$3.00

Previous CloseN/A

Volume24.00K

Average Volume (3M)47.79K

Market Cap

HK$1.29B

Enterprise ValueHK$1.27B

Total Cash (Recent Filing)HK$748.30M

Total Debt (Recent Filing)HK$72.40M

Price to Earnings (P/E)5.6

Beta0.41

Next Earnings

Aug 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.32

Shares Outstanding172,500,000

10 Day Avg. Volume34,000

30 Day Avg. Volume47,793

Financial Highlights & Ratios

PEG Ratio0.92

Price to Book (P/B)0.65

Price to Sales (P/S)1.22

P/FCF Ratio3.65

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High ProfitabilityConsistently elevated gross and net margins indicate durable operating economics and pricing power in specialty/generic drugs. High margins support internal reinvestment, buffer earnings during top-line softness, and underpin sustainable cash generation and shareholder returns over the medium term.

Conservative Balance SheetLow leverage and a growing equity base provide financial flexibility for R&D, capacity investment, or opportunistic M&A. A conservative capital structure reduces default risk, helps absorb cyclical shocks, and preserves strategic optionality over the next several quarters.

Solid Cash GenerationReliable free cash flow conversion supports funding of working capital, capex, and potential distributions without heavy external financing. Strong cash generation enhances resilience to revenue variability and enables disciplined capital allocation over the medium term.

Bears Say

Cooled Revenue MomentumA shift from rapid expansion to flat or slightly declining top line signals weaker organic demand or increased pricing/competitive pressure. Sustained weak revenue growth could force reliance on cost cuts or M&A to grow earnings, constraining long-term margin expansion and strategic flexibility.

Free Cash Flow VolatilityMaterial year-to-year swings in FCF reduce predictability for reinvestment, dividends, and debt servicing. Volatility raises the risk that cash shortfalls coinciding with capex or financing needs could force asset sales, higher borrowing, or curtailed investments in product development.

Rising Debt In 2023–2024An increase in debt, even from low levels, reduces headroom and increases interest exposure if rates rise. If revenue growth remains tepid, higher leverage could limit strategic choices, slow deleveraging, or pressure credit metrics over the next several quarters.

8049 FAQ

What was Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price range in the past 12 months?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H lowest stock price was HK$1.82 and its highest was HK$3.00 in the past 12 months.

What is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s market cap?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s market cap is HK$1.29B.

When is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s upcoming earnings report date?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s upcoming earnings report date is Aug 19, 2026 which is in 47 days.

How were Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s earnings last quarter?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H released its earnings results on Mar 31, 2026. The company reported HK$0.187 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.187.

Is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H overvalued?

According to Wall Street analysts Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H pay dividends?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H pays a Notavailable dividend of HK$0.287 which represents an annual dividend yield of N/A. See more information on Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H dividends here

What is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s EPS estimate?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H have?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H has 172,500,000 shares outstanding.

What happened to Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price movement after its last earnings report?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H reported an EPS of HK$0.187 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.315%.

Which hedge fund is a major shareholder of Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H?

Currently, no hedge funds are holding shares in HK:8049

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H

Jilin Province Huinan Changlong Bio-pharmacy Company Limited focuses on the manufacturing and sale of traditional Chinese medicines and various pharmaceutical products within the People's Republic of China. The company's extensive product portfolio includes a wide range of dosage forms such as tablets, capsules, and pills, as well as specialized items like Chinese medicine pretreatment and extraction products. They also provide various injectable solutions, including powders for injection, lyophilized powders for injection, and small volume liquid injections, along with active pharmaceutical ingredients (APIs) and granules. These products are primarily sold under the "Changlong" and "Qing Tong" brand names. Established in 1989, and headquartered in Kowloon, Hong Kong, the company was previously known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited.